PMID- 20678207
OWN - NLM
STAT- MEDLINE
DCOM- 20101130
LR  - 20211020
IS  - 1758-2652 (Electronic)
IS  - 1758-2652 (Linking)
VI  - 13
DP  - 2010 Aug 2
TI  - Immunological response to highly active antiretroviral therapy following 
      treatment for prevention of mother to child transmission of HIV-1: a study in 
      Cote d'Ivoire.
PG  - 28
LID - 10.1186/1758-2652-13-28 [doi]
AB  - BACKGROUND: Information is currently limited on the long-term follow up of HIV-1 
      infected women who are on highly active antiretroviral therapy (HAART) that 
      contains nevirapine and lamivudine and who were previously exposed to 
      antiretroviral drugs for the prevention of mother to child transmission (PMTCT) 
      of HIV. METHODS: We studied the 36-month immunological response to HAART in HIV-1 
      infected women in Cote d'Ivoire. The women were previously exposed to 
      antiretroviral drug regimens for PMTCT, including single-dose nevirapine and/or 
      short-course zidovudine with or without lamivudine. All HAART regimens included a 
      non-nucleoside reverse transcriptase inhibitor. RESULTS: At 36 months: the median 
      absolute increase in CD4+ T cell count was +359 cells/mm3 (IQR: 210-466) in 200 
      women who had undergone 36-month follow-up visits; +359 cells/mm3 (IQR: 222-491) 
      in 88 women not exposed to PMTCT antiretrovirals; and +363 cells/mm3 (IQR: 
      200-464) in 112 women exposed to at least one antiretroviral PMTCT regimen. 
      Overall, 49 (19.8%) of the 247 women who initiated HAART met the immunological 
      failure criteria at least once during follow up. The overall probability of 
      immunological failure was 0.08 (95% CI: 0.12-0.15) at 12 months, and 0.21 (95% 
      CI: 0.16-0.27) at 36 months. No difference was observed according to the presence 
      or absence of resistance mutations to nevirapine or lamivudine in women tested at 
      four weeks postpartum. In addition, at 36 months, 23% of women were lost to 
      follow up, dead or had stopped their treatment. CONCLUSIONS: A non-nucleoside 
      reverse transcriptase inhibitor-based antiretroviral regimen, initiated a year or 
      more after PMTCT exposure and that includes nevirapine, remains a good option for 
      at least the first 36 months of treatment.
FAU - Ekouevi, Didier K
AU  - Ekouevi DK
AD  - Centre de recherche, Inserm U 897, Bordeaux France. ekouevi@aviso.ci
FAU - Coffie, Patrick A
AU  - Coffie PA
FAU - Chaix, Marie-Laure
AU  - Chaix ML
FAU - Tonwe-Gold, Besigin
AU  - Tonwe-Gold B
FAU - Amani-Bosse, Clarisse
AU  - Amani-Bosse C
FAU - Leroy, Valeriane
AU  - Leroy V
FAU - Abrams, Elaine J
AU  - Abrams EJ
FAU - Dabis, Francois
AU  - Dabis F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100802
PL  - Switzerland
TA  - J Int AIDS Soc
JT  - Journal of the International AIDS Society
JID - 101478566
RN  - 0 (Anti-HIV Agents)
RN  - 2T8Q726O95 (Lamivudine)
RN  - 4B9XT59T7S (Zidovudine)
RN  - 99DK7FVK1H (Nevirapine)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/*therapeutic use
MH  - *Antiretroviral Therapy, Highly Active
MH  - CD4 Lymphocyte Count
MH  - Cote d'Ivoire
MH  - Female
MH  - HIV Infections/*drug therapy/*immunology/virology
MH  - HIV-1/isolation & purification
MH  - Humans
MH  - Infectious Disease Transmission, Vertical/*prevention & control
MH  - Lamivudine/therapeutic use
MH  - Nevirapine/therapeutic use
MH  - Treatment Outcome
MH  - Zidovudine/therapeutic use
PMC - PMC2925333
EDAT- 2010/08/04 06:00
MHDA- 2010/12/14 06:00
PMCR- 2010/08/02
CRDT- 2010/08/04 06:00
PHST- 2009/12/17 00:00 [received]
PHST- 2010/08/02 00:00 [accepted]
PHST- 2010/08/04 06:00 [entrez]
PHST- 2010/08/04 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
PHST- 2010/08/02 00:00 [pmc-release]
AID - 1758-2652-13-28 [pii]
AID - 10.1186/1758-2652-13-28 [doi]
PST - epublish
SO  - J Int AIDS Soc. 2010 Aug 2;13:28. doi: 10.1186/1758-2652-13-28.